

# Yoshitaka Narita

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9242064/publications.pdf>

Version: 2024-02-01

77  
papers

2,360  
citations

257450

24  
h-index

223800

46  
g-index

81  
all docs

81  
docs citations

81  
times ranked

3205  
citing authors

#	ARTICLE	IF	CITATIONS
1	Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. <i>Acta Neuropathologica</i> , 2013, 126, 267-276.	7.7	315
2	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. <i>Acta Neuropathologica Communications</i> , 2016, 4, 79.	5.2	189
3	Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3282-3289.	1.6	126
4	Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigen A24 With Recurrent or Progressive Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2011, 29, 337-344.	1.6	104
5	Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. <i>Cancer Science</i> , 2012, 103, 587-592.	3.9	87
6	Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 887-895.	1.3	85
7	Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium. <i>Neuro-Oncology</i> , 2019, 21, 1565-1577.	1.2	74
8	Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy. <i>Acta Neuropathologica</i> , 2016, 131, 889-901.	7.7	70
9	IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. <i>International Journal of Oncology</i> , 2012, 41, 1325-1336.	3.3	67
10	Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. <i>Brain Tumor Pathology</i> , 2015, 32, 22-30.	1.7	65
11	Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas. <i>Acta Neuropathologica</i> , 2017, 133, 445-462.	7.7	64
12	A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 348-359.	1.2	63
13	TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 323-338.	7.7	58
14	Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 587-595.	1.3	57
15	Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. <i>Acta Neuropathologica</i> , 2015, 129, 789-808.	7.7	45
16	Secondary hematological malignancies associated with temozolomide in patients with glioma. <i>Neuro-Oncology</i> , 2013, 15, 1445-1450.	1.2	44
17	Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab067.	0.7	42
18	Strategy of surgery and radiation therapy for brain metastases. <i>International Journal of Clinical Oncology</i> , 2009, 14, 275-280.	2.2	41

#	ARTICLE	IF	CITATIONS
19	Bevacizumab for glioblastoma. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1759.	2.0	36
20	A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis. <i>Neuro-Oncology Practice</i> , 2016, 3, 272-280.	1.6	34
21	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2723-2733.	7.0	33
22	Long-term follow-up of vanishing tumors in the brain: How should a lesion mimicking primary CNS lymphoma be managed?. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 1217-1221.	1.4	31
23	DNA demethylation is associated with malignant progression of lower-grade gliomas. <i>Scientific Reports</i> , 2019, 9, 1903.	3.3	31
24	Clinical presentation of anaplastic large-cell lymphoma in the central nervous system. <i>Molecular and Clinical Oncology</i> , 2013, 1, 655-660.	1.0	30
25	Risk factors for early death after surgery in patients with brain metastases: reevaluation of the indications for and role of surgery. <i>Journal of Neuro-Oncology</i> , 2014, 116, 145-152.	2.9	26
26	MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis. <i>World Neurosurgery</i> , 2018, 112, e69-e73.	1.3	26
27	Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 511-521.	2.3	25
28	Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. <i>Modern Pathology</i> , 2021, 34, 688-700.	5.5	25
29	Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. <i>Pediatric Blood and Cancer</i> , 2010, 55, 577-579.	1.5	23
30	Comparison of Clinical Outcomes of Surgery Followed by Local Brain Radiotherapy and Surgery Followed by Whole Brain Radiotherapy in Patients With Single Brain Metastasis: Single-Center Retrospective Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e475-e480.	0.8	23
31	Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas. <i>Journal of Clinical Oncology</i> , 2019, 37, 2004-2004.	1.6	23
32	The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. <i>Neuro-Oncology</i> , 2023, 25, 326-336.	1.2	23
33	Pathological findings and prognostic factors in recurrent glioblastomas. <i>Brain Tumor Pathology</i> , 2012, 29, 192-200.	1.7	22
34	Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas. <i>Brain Tumor Pathology</i> , 2013, 30, 224-232.	1.7	20
35	A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy. <i>Neuropathology</i> , 2013, 33, 576-581.	1.2	20
36	Usefulness of a glass-free medical three-dimensional autostereoscopic display in neurosurgery. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2014, 9, 905-911.	2.8	20

#	ARTICLE	IF	CITATIONS
37	p53 abnormality and tumor invasion in patients with malignant astrocytoma. <i>Brain Tumor Pathology</i> , 2010, 27, 95-101.	1.7	19
38	Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥75 years. <i>Radiation Oncology</i> , 2019, 14, 200.	3.7	19
39	Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. <i>Cancer Science</i> , 2021, 112, 5020-5033.	3.9	19
40	Toxicity and Outcome of Radiotherapy with Concomitant and Adjuvant Temozolomide in Elderly Patients with Glioblastoma: A Retrospective Study. <i>Neurologia Medico-Chirurgica</i> , 2014, 54, 272-279.	2.2	18
41	Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma. <i>Acta Neuropathologica</i> , 2017, 133, 321-324.	7.7	18
42	Health-related quality of life in long-term survivors with Grade II gliomas: the contribution of disease recurrence and Karnofsky Performance Status. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 906-913.	1.3	16
43	Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 31-39.	1.3	15
44	Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts. <i>Neuro-Oncology</i> , 2022, 24, 1246-1258.	1.2	14
45	Reactivation of Hepatitis B Virus After Glioblastoma Treatment With Temozolomide -Case Report-. <i>Neurologia Medico-Chirurgica</i> , 2011, 51, 728-731.	2.2	11
46	Management of Cytomegalovirus Infection in a Patient with Malignant Glioma Treated with Temozolomide and Steroids. <i>Internal Medicine</i> , 2012, 51, 2967-2971.	0.7	10
47	Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. <i>Molecular and Clinical Oncology</i> , 2013, 1, 995-1001.	1.0	10
48	Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status. <i>Brain Tumor Pathology</i> , 2012, 29, 183-191.	1.7	9
49	Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy. <i>Molecular and Clinical Oncology</i> , 2016, 5, 179-185.	1.0	8
50	Surgical outcome and graded prognostic assessment of patients with brain metastasis from adult sarcoma: multi-institutional retrospective study in Japan. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1995-2005.	2.2	8
51	Low tumor cell content predicts favorable prognosis in germinoma patients. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab110.	0.7	8
52	Management of glioblastoma in an NF1 patient with moyamoya syndrome: a case report. <i>Child's Nervous System</i> , 2013, 29, 341-345.	1.1	7
53	Outcomes of Surgery followed by Local Brain Radiotherapy Compared with Surgery followed by Whole Brain Radiotherapy for Single Brain Metastasis. <i>Tumori</i> , 2017, 103, 367-373.	1.1	7
54	Clinical outcomes of brain metastases from hepatocellular carcinoma: a multicenter retrospective study and a literature review. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1095-1100.	2.2	7

#	ARTICLE	IF	CITATIONS
55	Necessity for craniospinal irradiation of germinoma with positive cytology without spinal lesion on MR imaging—A controversy. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab086.	0.7	7
56	Current Knowledge and Treatment Strategies for Grade II Gliomas. <i>Neurologia Medico-Chirurgica</i> , 2013, 53, 429-437.	2.2	6
57	Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 787-793.	1.3	6
58	A case of unclassified high-grade glioma with polar spongioblastoma pattern. <i>Neuropathology</i> , 2012, 32, 604-610.	1.2	5
59	Development of an EORTC questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumours: phase III. <i>Quality of Life Research</i> , 2021, 30, 1491-1502.	3.1	5
60	MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas. <i>Journal of Neuro-Oncology</i> , 2022, 157, 561-571.	2.9	5
61	Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults. <i>Progress in Neurological Surgery</i> , 2018, 31, 145-151.	1.3	4
62	The clinical characteristics and outcomes of incidentally discovered glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 551-557.	2.9	4
63	Review of the diagnosis and treatment of brain metastases. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 3-7.	1.3	4
64	Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment**. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1028-1035.	1.3	3
65	Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas. <i>Neurology</i> , 2021, 97, e2114-e2123.	1.1	3
66	Evaluation of the efficacy and safety of TASO313 in adults with recurrent glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2703-2715.	4.2	3
67	Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas. <i>Cancers</i> , 2022, 14, 2454.	3.7	3
68	Reactivation of cytomegalovirus following treatment of malignant glioma with temozolomide. <i>International Cancer Conference Journal</i> , 2012, 1, 53-57.	0.5	2
69	The necessity of long-term follow-up including spinal examination after successful initial treatment of intracranial germinoma: case reports. <i>Child's Nervous System</i> , 2016, 32, 547-551.	1.1	2
70	Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma. <i>Radiation Oncology</i> , 2022, 17, 85.	2.7	2
71	Clinical Study for Malignant Brain Tumors by JCOG Brain Study Group. <i>Japanese Journal of Neurosurgery</i> , 2016, 25, 566-578.	0.0	1
72	Epidemiology and Standard Therapy in Gliomas (<Special Issue>Current Status and Perspectives of) <i>Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50</i>	0.0	1

#	ARTICLE	IF	CITATIONS
73	Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient's IADL?. <i>Neuro-Oncology Practice</i> , 2022, 9, 271-283.	1.6	1
74	Current Evidence and Future Direction in Treating Adult Grade II and III Gliomas. <i>Japanese Journal of Neurosurgery</i> , 2018, 27, 82-90.	0.0	0
75	Molecular Diagnosis in WHO Classification of Tumours of the Central Nervous System 2016 : A Domestic Survey and Perspectives. <i>Japanese Journal of Neurosurgery</i> , 2019, 28, 674-685.	0.0	0
76	EPID-09. THE INCIDENCE OF PRIMARY BRAIN TUMORS IN CHILDREN IN JAPAN BASED ON 2016 NATIONAL CANCER REGISTRY IN JAPAN. <i>Neuro-Oncology</i> , 2020, 22, iii320-iii320.	1.2	0
77	COT-6 Body mass index and height in relation to brain tumor risk in a Japanese population. <i>Neuro-Oncology Advances</i> , 2021, 3, vi29-vi29.	0.7	0